Benitec Biopharma Inc.
For the period ended Jun 30, 2025. Filed Sep 22, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 22, 2025
BNTC$9.28-6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year Ended | ||
|---|---|---|
| June 30, | ||
| 2025 | 2024 | |
| Operating expenses | ||
| Royalties and license fees | $— | $(108) |
| Research and development | 18,332 | 15,609 |
| General and administrative | 23,433 | 6,989 |
| Total operating expenses | 41,765 | 22,490 |
| Loss from operations | (41,765) | (22,490) |
| Other income (loss): | ||
| Foreign currency transaction gain (loss) | (71) | 40 |
| Interest income (expense), net | 3,286 | 904 |
| Other expense, net | (131) | (204) |
| Gain on extinguishment of liabilities | 764 | — |
| Unrealized loss on investment | — | (1) |
| Total other income (loss), net | 3,848 | 739 |
| Net loss | $(37,917) | $(21,751) |
| Other comprehensive income: | ||
| Unrealized foreign currency translation gain (loss) | 53 | (62) |
| Total other comprehensive income (loss) | 53 | (62) |
| Total comprehensive loss | $(37,864) | $(21,813) |
| Net loss | $(37,917) | $(21,751) |
| Deemed dividends | — | (619) |
| Net loss attributable to common shareholders | $(37,917) | $(22,370) |
| Net loss per share: | ||
| Basic and diluted | $(1.05) | $(1.22) |
| Weighted average number of shares outstanding: basic and diluted | 36,209,271 | 18,364,386 |
F-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.